Near-sightedness

Nordic Eyewear Market Insights & Forecasts Report 2024-2028 with Competitive Analysis of Grand Vision, Synsam, Specsavers, Synologen, Optik Team, and Krogh Optikk - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024

The "Nordic Eyewear Market (Sweden, Denmark, Norway & Finland): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nordic Eyewear Market (Sweden, Denmark, Norway & Finland): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • The Nordic eyewear market can be categorized into the following sectors Spectacles, Contact Lenses, and Sunglasses.
  • In 2023, the dominant share of Nordic eyewear market was held by Sweden, followed by Denmark, Norway, and Finland.
  • The report provides a comprehensive analysis of the Nordic eyewear market.

STAAR Surgical to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 6, 2024

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences:

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences:
    Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12
    Management will also meet with investors in Shenzhen and Shanghai, China, from Monday, March 18 through Wednesday, March 20.
  • Investor participation is by invitation from each sponsoring brokerage firm.

Seoul Semiconductor Showcases The World’s First Technology at the Lighting Trade Exhibition in Germany

Retrieved on: 
Monday, March 4, 2024

Seoul Semiconductor (KOSDAQ:046890) will participate in Light + Building 2024 , the world’s largest lighting trade exhibition to be held in Frankfurt, Germany from the 3rd to the 8th of March.

Key Points: 
  • Seoul Semiconductor (KOSDAQ:046890) will participate in Light + Building 2024 , the world’s largest lighting trade exhibition to be held in Frankfurt, Germany from the 3rd to the 8th of March.
  • At the event, Seoul Semiconductor will showcase its exclusive and the world’s first LED lighting solutions of the highest efficiency and highest quality of light Spectrum.
  • View the full release here: https://www.businesswire.com/news/home/20240304168366/en/
    The world’s first second-generation LED technology developed by Seoul Semiconductor (Graphic: Seoul Semiconductor Co., Ltd.)
    Seoul Semiconductor is expected to unveil its ‘WICOP’ technology-based high-efficiency lighting system of 240 lumens per watt (lm/W), which is still the leading industry standard.
  • In addition, Seoul Semiconductor will also feature its ‘SunLike’ technology of the highest quality of light Spectrum.

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Monday, February 26, 2024

Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.

Key Points: 
  • Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.
  • Product mix favorably impacted gross margin in the fourth quarter of 2023 as compared to the prior year quarter.
  • Operating expenses for the fourth quarter of 2023 were $50.3 million compared to the prior year quarter of $48.8 million.
  • Operating income for the fourth quarter of 2023 was $10.4 million or 13.7% of net sales as compared to $1.0 million or 1.5% of net sales for the fourth quarter of 2022.

STAAR Surgical to Report Fourth Quarter Results on February 26, 2024

Retrieved on: 
Monday, February 19, 2024

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.
  • STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call please dial 877-270-2148 for domestic participants and 412-902-6510 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

SightGlass Vision Receives Breakthrough Device Designation from U.S. Food and Drug Administration

Retrieved on: 
Wednesday, February 14, 2024

LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- SightGlass Vision, a joint venture of CooperCompanies and EssilorLuxottica that develops innovative technologies and science-based treatments to address the global myopia epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its Diffusion Optics Technology™ (DOT™) spectacle lenses, which are intended to slow myopia progression in children. The unique design is the first to use the contrast management mechanism of action, incorporating thousands of elements that gently scatter light across the retina.

Key Points: 
  • The FDA's Breakthrough Devices Program is for highly innovative devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.
  • Manufacturers are given more frequent opportunities for FDA feedback during the premarket review phase, as well as a prioritized submission review.
  • Since the program's introduction in 2015, only 18 other ophthalmic devices have received the Breakthrough Device designation.
  • *
    "The FDA Breakthrough Device designation for Diffusion Optics Technology™ (DOT™) spectacle lenses is a milestone for our organization—and for the broader fight against the pediatric myopia epidemic.

The Waring Vision Institute's Dr. George Waring IV will be the First in the Nation to Introduce TENEO™ Technology to Patients

Retrieved on: 
Thursday, February 8, 2024

CHARLESTON, S.C., Feb. 8, 2024 /PRNewswire/ -- Dr. George Waring IV of The Waring Vision Institute (Mt. Pleasant, SC ) will be the first in the nation to perform patient treatments on the just approved TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism. "The precise engineering of this platform delivers a fast, small, technologically advanced machine that provides an exceptional experience for both surgeons and patients," said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb. He added, "We are excited to partner with Dr. Waring and the professionals at the Waring Vision Institute to launch this important vision enhancement technology in the U.S."

Key Points: 
  • Pleasant, SC ) will be the first in the nation to perform patient treatments on the just approved TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism.
  • "The precise engineering of this platform delivers a fast, small, technologically advanced machine that provides an exceptional experience for both surgeons and patients," said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb.
  • He added, "We are excited to partner with Dr. Waring and the professionals at the Waring Vision Institute to launch this important vision enhancement technology in the U.S."
    "FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology," said George Waring IV, M.D., ophthalmologist, founder and medical director, Waring Vision Institute.
  • Dr. George Waring IV is Founder and Medical Director of the Waring Vision Institute , South Carolina.

Located in Seoul, Korea, Topcon Korea Medical Co., Ltd. (TKM) Was Established and Formally Launched in 2023.

Retrieved on: 
Friday, February 2, 2024

Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon Healthcare) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President: Artur Chu) (henceforth TKM) to strengthen and expand its eyecare business in South Korea.

Key Points: 
  • Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon Healthcare) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President: Artur Chu) (henceforth TKM) to strengthen and expand its eyecare business in South Korea.
  • In South Korea, as in other developed countries, the government is responding to the increase in eye disease associated with an aging population.
  • "Introducing Topcon Korea Medical Co., Ltd., empowering excellence in the Korean market.
  • With a firm foundation built on understanding the needs of our customers in Korea, TKM is poised to revolutionize the industry landscape.

Lindus Health Introduces Bespoke "All-In-One CRO for Digital Therapeutics" Solution to Companies in the Space Streamline Clinical Trials

Retrieved on: 
Thursday, February 1, 2024

Lindus Health's new offering for the DTx market bundles the services of an experienced CRO in DTx.

Key Points: 
  • Lindus Health's new offering for the DTx market bundles the services of an experienced CRO in DTx.
  • This offering is intended to produce a true "one-stop-shop" experience for everything needed to run a DTx clinical trial.
  • Technology-driven recruitment services: Lindus Health employs a variety of different strategies to accelerate DTx trials.
  • Lindus Health's "All-In-One CRO" offering enables DTx companies to achieve study milestones faster through their tech-forward and patient-centric approach to executing clinical trials.

NEW REPORT REVEALS COST OF UNMANAGED SCREEN TIME SYMPTOMS TO BE $151 BILLION PER YEAR

Retrieved on: 
Tuesday, January 30, 2024

ST. LOUIS, Jan. 30, 2024 /PRNewswire/ -- Today, the American Optometric Association (AOA), the leading authority on and advocate for quality eye health care, in conjunction with the Deloitte Economics Institute released a report, The impact of unmanaged excessive screen time in the United States,1 to understand the implications of unmanaged screen time in the United States and how doctors of optometry can play an essential role in preventing further costs through annual comprehensive exams.

Key Points: 
  • As little as two hours of screen exposure per day can induce digital eye strain symptoms which can cause discomfort and take a toll on an individual's quality of life.
  • Almost 70% of individuals working in offices jobs are exposed to excessive screen time compared to 42% of individuals in other professions.
  • 31.8 million people, or 31% of the population surveyed, exposed to excessive screen time did not see an optometrist in the last 12 months.
  • "Through this report, we have even more data showing that not visiting a doctor of optometry can have notable cost implications and potentially reduce quality of life.